Novozymes and Syngenta Enter Global Commercial Agreement
News Oct 26, 2012
Novozymes and Syngenta announced an exclusive global marketing and distribution agreement on the microbial-based biofungicide Taegro®, a natural solution with multiple modes of action used to combat fungal diseases across various crops. The two companies will join forces to bring Novozymes’ Taegro to farmers worldwide through Syngenta’s global organization.
“This collaboration matches Syngenta’s global market strength and leading position within fungicides and integrated solutions with Novozymes’ deep know-how on sustainable, biobased technologies,” says Thomas Videbæk, Executive Vice President of Novozymes. “Using technology developed by Novozymes, Syngenta will provide farmers all over the world with a biological product to help sustainably combat fungal diseases in a powerful manner.”
“We're delighted to enter into another agreement to commercialize a Novozymes technology. Having worldwide commercial rights for Taegro will further strengthen our ability to offer high-performing integrated crop solutions,” comments John Atkin, Chief Operating Officer of Syngenta.
Combatting fungal diseases with sustainable technologies
Taegro offers a biological solution in the form of a microbial-based fungicide, based on the naturally occurring Bacillus subtilis bacterium, which is complementary to existing fungicide technology. It effectively targets fungal diseases such as Rhizoctonia and Fusarium on fruit and vegetables, and its application is expected to be expanded to a wider portfolio of broad-acre crops such as wheat, soy and corn.
Companies to share task of bringing technology to market
Under the terms of the agreement, Novozymes and Syngenta will share the task of bringing Taegro to market. Syngenta will be responsible for sales, marketing and distribution, while Novozymes will be responsible for production and registration. Trials are planned to secure data to continue to build on the current U.S. registration in other regions, following which the two companies aim for a global rollout.
Financial details about the agreement are not being disclosed.
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.
Ancient Syphilis Genomes Decoded for First TimeNews
Researchers recovered three genomes of the bacterium Treponema pallidum from skeletal remains from colonial-era Mexico, and were able to distinguish the subspecies that causes syphilis from the subspecies that causes yaws. It was not previously thought possible to recover DNA from this bacterium from ancient samples.